Mohammed Ullah

1.2k citations
25 papers · 1k · h-index 17

Impact in

  • Pharmacology top 2%
    • Pharmacogenetics and Drug Metabolism
    • Drug-Induced Hepatotoxicity and Protection
  • Genetics top 5%
    • Neurogenetic and Muscular Disorders Research

Papers in

  • Oncology 14
    • Drug Transport and Resistance Mechanisms 14
  • Pharmacology 7
    • Pharmacogenetics and Drug Metabolism 6
Co-authors
Agnès Poirier (4 shared papers)Claudia Senn (3 shared papers)Katherine S. Fenner (3 shared papers)Kenichi Umehara (4 shared papers)Fenghua Hu (3 shared papers)Tuancheng Feng (3 shared papers)Christoph Funk (3 shared papers)Jashvant D. Unadkat (3 shared papers)
Journals
Drug Metabolism and Disposition (7 papers)Journal of Pharmacology and Experimental Therapeutics (2 papers)mAbs (1 paper)EMBO Reports (1 paper)Xenobiotica (1 paper)
Partner nations
SwitzerlandUnited StatesUnited Kingdom

In The Last Decade

Mohammed Ullah

25 papers receiving 969 citations

Peers

Mohammed Ullah
Comparison fields: 5 of 68
  • Pharmacology 244
  • Genetics 144
  • Oncology 333
  • Neurology 68
  • Neurology 28
Replace Sonia M. de Morais with:
Sonia M. de Morais United States
Brian A. Staton United States
Jens Lamerz Switzerland
Heike Knüpfer Germany
Hirotaka Kawakami Japan
Anne Gardin Switzerland
Dan Yu China
Yuanyuan Huang China
Bingyi Wu China
Giselle Pinto de Faria Lopes Brazil
Mohammed Ullah relative to Sonia M. de Morais United States Sonia M. de Morais's profile →
Citations per field
00.5×5×10×17×
Sonia M. de Morais · 1×
Citations per year

Countries citing papers authored by Mohammed Ullah

Since Specialization
Citations

This map shows the geographic impact of Mohammed Ullah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed Ullah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed Ullah more than expected).

Fields of papers citing papers by Mohammed Ullah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed Ullah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed Ullah. The network helps show where Mohammed Ullah may publish in the future.

Co-authors

The 25 scholars most cited alongside Mohammed Ullah, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mohammed Ullah Line = papers co-authored together Mohammed Ullah links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs
Pharmacology Research & Perspectives ·Agnès Poirier, Marla L. Weetall, Katja Heinig, Franz Bucheli, Kerstin Schoenlein, Jochem Alsenz, Mohammed Ullah, Claudia Senn
2018144
2
Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations
Clinical Pharmacology & Therapeutics ·Kunal S. Taskar, Venkatesh Pilla Reddy, Howard J. Burt, Maria M. Posada, Manthena V. S. Varma, Mohammed Ullah, Arian Emami Riedmaier, Kenichi Umehara
2019133
3
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
Neuro-Oncology ·Holger Fischer, Mohammed Ullah, Cecile C. de la Cruz, Thomas Hunsaker, Claudia Senn, Thomas Wirz, Björn Wagner, Dragomir Ivanov Draganov
202076
4
Minimizing DILI risk in drug discovery — A screening tool for drug candidates
Toxicology in Vitro ·Simone Schadt, Silke Simon, Stefan Kustermann, Franziska Boess, Connor McGinnis, Andreas Brink, R. Lieven, Stephen M. Fowler
201575
5
Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice
EMBO Reports ·Tuancheng Feng, Shuyi Mai, Jenn Marie Roscoe, Ruoyu Sheng, Mohammed Ullah, Isabel Iscol Katz, Haiyuan Yu, Wenjun Xiong
202073
6
Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC 50 and [I 2 ]/IC 50 , That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction Studies
Molecular Pharmaceutics ·Jack Cook, Bo Feng, Katherine S. Fenner, Sarah Kempshall, Ray Liu, Charles J. Rotter, Dennis A. Smith, Matthew D. Troutman
200949
7
The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance
Xenobiotica ·Katherine S. Fenner, Hannah M. Jones, Mohammed Ullah, Sarah Kempshall, Maurice Dickins, Yurong Lai, Paul Morgan, Hugh A. Barton
201142
8
A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination
Brain ·Tuancheng Feng, Ruoyu Sheng, Santiago Solé‐Domènech, Mohammed Ullah, Xiaolai Zhou, Christina S. Mendoza, Laura Camila Martinez Enriquez, Isabel Iscol Katz
202041
9
Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo
Drug Metabolism and Disposition ·Agnès Poirier, Anne‐Christine Cascais, Urs Bader, Renée Portmann, Marie-Elise Brun, Isabelle Walter, Alexander Hillebrecht, Mohammed Ullah
201440
10
Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics
Drug Metabolism and Disposition ·Kazuya Ishida, Mohammed Ullah, Viktória Juhász, Jashvant D. Unadkat +1 other
201740
11
The Need for Human Breast Cancer Resistance Protein Substrate and Inhibition Evaluation in Drug Discovery and Development: Why, When, and How?
Drug Metabolism and Disposition ·Agnès Poirier, Renée Portmann, Anne‐Christine Cascais, Urs Bader, Isabelle Walter, Mohammed Ullah, Christoph Funk
201439
12
Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues
Analytica Chimica Acta ·Chengjie Ji, William R. Tschantz, Nathan D. Pfeifer, Mohammed Ullah, Nalini Sadagopan
201137
13
Application of the Extended Clearance Classification System (ECCS) in Drug Discovery and Development: Selection of Appropriate In Vitro Tools and Clearance Prediction
Drug Metabolism and Disposition ·Kenichi Umehara, Carina Cantrill, Matthias Wittwer, Elisa Di Lenarda, Florian Klammers, Aynur Ekiciler, Neil John Parrott, Stephen M. Fowler
202036
14
In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions
Drug Metabolism and Disposition ·Eric L. Reyner, Samantha Sevidal, Mark A. West, Andrea Clouser-Roche, Sascha Freiwald, Katherine S. Fenner, Mohammed Ullah, Caroline A. Lee
201334
15
TMEM106B deficiency impairs cerebellar myelination and synaptic integrity with Purkinje cell loss
Acta Neuropathologica Communications ·Tuancheng Feng, Lin Luan, Isabel Iscol Katz, Mohammed Ullah, Vivanna M. Van Deerlin, John Q. Trojanowski, Edward Lee, Fenghua Hu
202223
16
Towardin vitro-to-in vivotranslation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms
mAbs ·Claudia A. Castro Jaramillo, Sara Belli, Anne‐Christine Cascais, Sherri Dudal, Martin R. Edelmann, Markus Haak, Marie-Elise Brun, Michael B. Otteneder
201720
17
Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides
Drug Metabolism and Disposition ·Kazuya Ishida, Mohammed Ullah, Viktória Juhász, Jashvant D. Unadkat +1 other
201818
18
Addressing Today’s Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam
Drug Metabolism and Disposition ·Stephen M. Fowler, Andreas Brink, Yumi Cleary, Andreas Günther, Katja Heinig, Christophe Husser, Heidemarie Kletzl, Nicole A. Kratochwil
202116
19
Calculation of an Apical Efflux Ratio from P-Glycoprotein (P-gp) In Vitro Transport Experiments Shows an Improved Correlation with In Vivo Cerebrospinal Fluid Measurements in Rats: Impact on P-gp Screening and Compound Optimization
Journal of Pharmacology and Experimental Therapeutics ·Holger Fischer, Claudia Senn, Mohammed Ullah, Carina Cantrill, Franz Schuler, Li J. Yu
202014
20
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
Investigational New Drugs ·Georgina Meneses‐Lorente, Stephen M. Fowler, Elena Guerini, Karey Kowalski, Edna Chow‐Maneval, Li J. Yu, Mohammed Ullah, Kenichi Umehara
202114

About Mohammed Ullah

Mohammed Ullah is a scholar working on Oncology, Pharmacology, Genetics, Neurology and Developmental Neuroscience, having authored 25 papers that have together received 1k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (14 papers), Pharmacogenetics and Drug Metabolism (6 papers), Neurogenetic and Muscular Disorders Research (2 papers), Lysosomal Storage Disorders Research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Amyotrophic Lateral Sclerosis Research (2 papers), Pharmaceutical studies and practices (1 paper) and Olfactory and Sensory Function Studies (1 paper). The work is most often cited by research in Pharmacology (244 citations), Genetics (144 citations), Oncology (333 citations), Neurology (68 citations) and Neurology (28 citations). Mohammed Ullah has collaborated with scholars based in Switzerland, United States and United Kingdom. Frequent co-authors include Agnès Poirier, Claudia Senn, Katherine S. Fenner, Kenichi Umehara, Fenghua Hu, Tuancheng Feng, Christoph Funk, Jashvant D. Unadkat, Kazuya Ishida and Katja Heinig. Their work appears in journals such as Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, mAbs, EMBO Reports and Xenobiotica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sonia M. de MoraisBreakdown of academic impact, for papers by Brian A. StatonBreakdown of academic impact, for papers by Jens LamerzBreakdown of academic impact, for papers by Heike KnüpferBreakdown of academic impact, for papers by Hirotaka KawakamiBreakdown of academic impact, for papers by Anne GardinBreakdown of academic impact, for papers by Dan YuBreakdown of academic impact, for papers by Yuanyuan HuangBreakdown of academic impact, for papers by Bingyi WuBreakdown of academic impact, for papers by Giselle Pinto de Faria Lopes